MiMedx Group Inc  

(Public, NASDAQ:MDXG)   Watch this stock  
Find more results for MDXG
12.50
+0.36 (2.97%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.04 - 13.07
52 week 7.64 - 17.47
Open 12.17
Vol / Avg. 6.63M/1.86M
Mkt cap 1.39B
P/E 41.14
Div/yield     -
EPS 0.30
Shares 111.03M
Beta 0.87
Inst. own 70%
Dec 13, 2017
MiMedx Group Inc 2018 Guidance And Shareholder Conference Call - Webcast
Nov 30, 2017
MiMedx Group Inc Corporate Analyst Meeting - Webcast
Nov 29, 2017
MiMedx Group Inc at Piper Jaffray Healthcare Conference
Nov 16, 2017
MiMedx Group Inc at Jefferies Global Healthcare Conference
Nov 9, 2017
MiMedx Group Inc at Canaccord Genuity Medical Technologies & Diagnostics Forum
Oct 27, 2017
Q3 2017 MiMedx Group Inc Earnings Call - Webcast
Oct 11, 2017
MiMedx Group Inc Q3 2017 Revenues Guidance Call - Webcast
Oct 11, 2017
MiMedx Group Inc at Janney Osteoarthritis Pain Conference
Sep 26, 2017
MiMedx Group Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 21, 2017
MiMedx Group, Inc. - Shareholder/Analyst Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 20.64% 4.89%
Operating margin 15.51% 7.53%
EBITD margin - 9.76%
Return on average assets 36.99% 7.28%
Return on average equity 48.33% 9.94%
Employees 690 -
CDP Score - -

Address

1775 W Oak Commons Ct
MARIETTA, GA 30062-2254
United States - Map
+1-678-3846720 (Phone)
+1-678-3846720 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Officers and directors

Parker H. Petit Jr. Chairman of the Board, Chief Executive Officer
Age: 77
Bio & Compensation  - Reuters
William Charles Taylor President, Chief Operating Officer, Director
Age: 48
Bio & Compensation  - Reuters
Michael J. Senken Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Alexandra O. Haden General Counsel, Secretary
Age: 42
Bio & Compensation  - Reuters
Charles E. Koob Director
Age: 72
Bio & Compensation  - Reuters
Luis A. Aguilar Independent Director
Age: 63
Bio & Compensation  - Reuters
Joseph G. Bleser Independent Director
Age: 71
Bio & Compensation  - Reuters
J. Terry Dewberry Independent Director
Age: 73
Bio & Compensation  - Reuters
Charles R. Evans Independent Director
Age: 70
Bio & Compensation  - Reuters